Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Transl Res. 2019 Nov 28;217:47–60. doi: 10.1016/j.trsl.2019.11.002

Figure 6.

Figure 6

Glyburide treatment results in comparable reductions in pro-inflammatory cytokines, chemokines, and growth factors to NLRP3−/−. Gene expression of the inflammatory cytokines (a) IL6 and (b) TNFα, chemokine (c) CCL2, inflammatory mediator (d) s100a8, and growth factors (e) VEGF, (f) FGF2 and (g) TGFβ. Values are presented as mean ± standard error. WT versus NLRP3−/− burn #p < 0.05; ##p < 0.01; ###p < 0.001, WT versus glyburide treated burn *p < 0.05; **p < 0.01; ***p< 0.001, NLRP3−/− versus glyburide treated burn p < 0.05; ◦◦p < 0.01; ◦◦◦p < 0.001, daily treated versus delayed treatment p < 0.05; ••p < 0.01; •••p<0.001.